| abstract |
The invention relates to the use of one or several alanyl-aminopeptidase inhibitors and/or enzyme inhibitors which exhibit the same substrate specificity in order to stimulate the production of TFG-beta 1 and the expression of TFG-beta 1 in and/or on lymphocyte T regulators. The invention also relates to the use of said inhibitors for preventing and/or curing autoimmune, allergic and cardiovascular diseases and to preclude the rejection of transplants. In addition, said invention relates to applications in which peptidic fragments of pathogenic autoantigens or synthetic analogues and/or specific antigenic components of pathogenic microorganisms are used. |